Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

ABSTRACT: Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

PROVIDER: PRJNA630493 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

Project description:Background. We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations. Results. NanoString data were available from 512 patients in the discovery ATE dataset. Elastic net identified a prognostic signature of nine genes (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L, PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores to an average z-score signature conserved the prognostic value of the ATE signature. The z-score signature was prognostic for OS in the ATE dataset (P < 0.0001), as expected, and in the validation cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.021; UCLA, P = 0.0037). The signature remained prognostic following adjustment for MGMT promoter methylation status or corticosteroid use at baseline. A positive correlation between the signature and proneural/proliferative subtypes was observed in patients with MGMT non-methylated promoter status. Conclusions. The ATE signature showed prognostic value and may enable clinical trial stratification for IDH wild-type glioblastoma.

2020-06-01 | GSE150614 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

2020-06-01 | GSE150612 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

2020-06-01 | GSE150604 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

2020-06-01 | GSE149921 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

| PRJNA632912 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

| PRJNA632908 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

| PRJNA632910 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

| PRJNA632915 | ENA

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Project description:This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

| 92735 | ecrin-mdr-crc